- Author:
Wen-Rui XU
1
;
Hong-Fang JIN
1
;
Jun-Bao DU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adrenergic alpha-Agonists; therapeutic use; Adrenergic beta-Antagonists; therapeutic use; Catecholamines; metabolism; Humans; Postural Orthostatic Tachycardia Syndrome; drug therapy; metabolism; pathology; therapy
- From: Chinese Medical Journal 2016;129(18):2241-2245
- CountryChina
- Language:English
-
Abstract:
OBJECTIVEPostural tachycardia syndrome (POTS) is one of the major causes of orthostatic intolerance in children. We systematically reviewed the pathogenesis and the progress of individualized treatment for POTS in children.
DATA SOURCESThe data analyzed in this review are mainly from articles included in PubMed and EMBASE.
STUDY SELECTIONThe original articles and critical reviews about POTS were selected for this review.
RESULTSStudies have shown that POTS might be related to several factors including hypovolemia, high catecholamine status, abnormal local vascular tension, and decreased skeletal muscle pump activity. In addition to exercise training, the first-line treatments mainly include oral rehydration salts, beta-adrenoreceptor blockers, and alpha-adrenoreceptor agonists. However, reports about the effectiveness of various treatments are diverse. By analyzing the patient's physiological indexes and biomarkers before the treatment, the efficacy of medication could be well predicted.
CONCLUSIONSThe pathogenesis of POTS is multifactorial, including hypovolemia, abnormal catecholamine state, and vascular dysfunction. Biomarker-directed individualized treatment is an important strategy for the management of POTS children.